Micro-Cap Mania: CODX and MAMK Spark Biotech and Sub-$1 Stock Rally
By ATTN Desk · Editorial oversight: Sean Han
Market Recap: October 27, 2025
The U.S. equity market saw pronounced volatility on October 27, 2025, as several small-cap and micro-cap names delivered outsized gains. Biotech and diagnostics stocks led the charge, supported by pipeline progress and legal developments, while low-priced issues attracted high trading volumes. Overall, the broader market maintained a cautiously optimistic tone amid sector-specific catalysts.
| Ticker | ATTN Price | Current Price | Volume | Price Change % |
|---|---|---|---|---|
| BKYI | 0.5175 | 1.0199 | 120,016,889 | 97.18% |
| NTLA | 11.4147 | 14.4900 | 33,649,669 | 26.88% |
| SLGB | 2.6855 | 3.0600 | 3,637,538 | 13.98% |
| SOHO | 2.0852 | 2.1303 | 4,671,442 | 2.13% |
| CLIK | 7.8401 | 10.1500 | 6,859,143 | 29.53% |
| CODX | 0.3662 | 0.9741 | 695,458,866 | 166.05% |
| RNA | 69.4241 | 70.0775 | 51,463,726 | 0.90% |
| TGL | 0.5395 | 0.8111 | 33,333,414 | 50.29% |
| RECT | 1.9886 | 3.1400 | 7,776,200 | 57.80% |
| KITT | 0.9717 | 1.8300 | 55,924,143 | 88.46% |
| DYN | 21.9131 | 23.7700 | 10,078,626 | 8.48% |
| ASST | 1.2228 | 1.6400 | 616,108,431 | 34.07% |
| WGRX | 0.6552 | 0.8010 | 18,264,907 | 22.29% |
| RPGL | 0.8436 | 1.2800 | 3,015,798 | 51.79% |
| EDN | 21.9824 | 26.5000 | 611,479 | 20.56% |
| LOMA | 8.8641 | 10.3000 | 2,742,686 | 16.18% |
| IRS | 13.4661 | 15.4000 | 692,084 | 14.32% |
| GSIT | 9.1389 | 12.1200 | 15,464,455 | 32.63% |
| MAMK | 0.7446 | 3.1700 | 3,038,968 | 326.00% |
Market Overview
Small-cap and micro-cap shares dominated today’s trading, as investors reacted to company-specific newsflows. Diagnostics specialist Co-Diagnostics, Inc. (CODX) led percentage gains, jumping over 166% on the heels of an at-the-market equity raise and dismissal of a class-action lawsuit. BIO-key International (BKYI) almost doubled after filing an 8-K and registering new equity plans, while Nauticus Robotics (KITT) rallied nearly 89% following its strategic alliance announcement with Leidos.
Volume was notably heavy in several sub-$1 names. CODX traded nearly 700 million shares, ASST topped 616 million, and BKYI surpassed 120 million. These outsized volumes reflect speculative interest in low-priced issues with fresh catalysts.
Notable Movers
CLIK, a blockchain infrastructure play, advanced 29.5% after unveiling plans for international expansion and a partnership in Southeast Asia. SLRR Biotech (SLGB) added nearly 14% amid positive trial readouts, while TGL surged 50.3% on news of a reverse merger filing. Meanwhile, Rectitude Holdings (RECT) posted a 57.8% gain after announcing a Bitcoin treasury strategy backed by a $32.6 million equity deal.
On the flip side, only a handful of names posted modest single-digit gains or stalled. With RNA Diagnostics (RNA) up less than 1%, investors appeared to rotate capital into higher-beta, event-driven equities.
Biotech Stocks by CDC
Sector and Pattern Analysis
The session highlighted two clear patterns: first, the continuous appetite for speculative biotech and diagnostics stocks with clinical or legal catalysts; second, heightened trading in sub-$1 securities, where fractional-share retail activity and momentum strategies remain prevalent.
Breadth within this micro-cap cohort was overwhelmingly positive, with every tracked ticker closing higher. Volume spikes in CODX, ASST and BKYI underscore the ongoing retail-driven rotation into names with outsized upside potential—but also elevated risk.
TL;DR
- Micro-cap issues surged broadly, led by CODX (+166%), MAMK (+326%) and BKYI (+97%).
- CODX’s rally followed an equity raise and lawsuit dismissal; BKYI jumped on 8-K filings and equity plan registrations.
- High trading volumes in CODX (695 M), ASST (616 M) and BKYI (120 M) signaled strong retail activity.
- Diagnostics, biotech and blockchain infrastructure were the day’s top sectors.
- Zero decliners: surveys of these 19 tickers showed uniform advances amid event-driven trading.